<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03311581</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(II)-20170080</org_study_id>
    <nct_id>NCT03311581</nct_id>
  </id_info>
  <brief_title>The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery</brief_title>
  <official_title>The Feasibility of Propofol TCI in Hemodialysis Patients Undergoing Arteriovenous Shunt Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Written informed consent must be obtained before any study specific procedures are
      undertaken. Informed consent will be obtained during pre-operative assessment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit 80 patients undergoing AV shunt surgery. All patients will
      receive general anesthesia and brachial plexus block. Patients will be randomly allocated
      into two groups. Study and control group received propofol target-controlled infusion (TCI)
      and inhaled anesthetics as anesthesia maintenance, respectively. Main outcomes will be
      assessed by perioperative blood pressure, heart rate, respiratory rate, end-tidal CO2,
      analgesics dosage, pain intensity and perioperative adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>The blood pressure change between baseline, post-induction 3mins, operation start, post-operation 10 mins,post-operation 30 mins,post-operation 1 hour,post-operation 2 hours, end of surgery, recovery room, up to 4 hours</time_frame>
    <description>Systolic blood pressure, diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>analgesics dosage</measure>
    <time_frame>The amount of analgesics dosage use at recovery room,an average of 4 hours</time_frame>
    <description>post-operation analgesics dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pain intensity</measure>
    <time_frame>The pain intensity change at recovery room, post-operation day 1, post-operation day 2</time_frame>
    <description>Visual Analog Score for pain</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Hemodialysis Complication</condition>
  <arm_group>
    <arm_group_label>Propofol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>propofol TCI plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sevoflurane group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sevoflurane 2~4 % plus brachial plexus block with ropivacaine 0.5% 30 to 40 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.</description>
    <arm_group_label>Propofol group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sevoflurane</intervention_name>
    <description>sevoflurane inhalation 2~4%</description>
    <arm_group_label>Sevoflurane group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Uremic adult(over20-year-old)patients under going arteriovenous (AV) shunt surgery

        Exclusion Criteria:

          -  one of below systemic diseases; chronic pulmonary, cardiac diseases(such as COPD,
             asthma, acute myoischemia), hepatic co-mobility(such as liver cirrhosis), morbid
             obesity, alcoholism, allergy to propofol and inhaled anesthetics, the women who are
             pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>I-Cheng Lu, MD</last_name>
    <phone>88673121101</phone>
    <phone_ext>3312</phone_ext>
    <email>u9251112@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>I-CHENG Lu, PhD</last_name>
      <phone>0975356677</phone>
      <email>u9251112@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 17, 2017</study_first_submitted>
  <study_first_submitted_qc>October 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2017</study_first_posted>
  <last_update_submitted>March 6, 2018</last_update_submitted>
  <last_update_submitted_qc>March 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Arteriovenous Fistula</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

